~~<i id='0093A5CC63'><strike id='0093A5CC63'><tt id='0093A5CC63'><pre id='0093A5CC63'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：leisure time 2025-09-30 05:04:03 - browse：29

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Antivenom research: Lessons from HIV applied in search for universal antidote

explore

focus

knowledge

hotspot

Wikipedia

AdobeLONDON—AdrugindevelopmentasaweightlosstreatmentsucceededinaPhase2studyinaseriouslivercondition,

WSS

Obesity drugs seen as possible treatment for liver disease MASH

Gene editing the human germline: What are the risks?

CVS Caremark has created a new ploy: the drug ‘rebate credit’

U.K. researchers warn about biases in medical devices, algorithms

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

New documents shed light on MD Anderson Cancer Institute feud

focus

fashion

explore

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Intermittent fasting comes with a heart risk? Not so fast

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

With competition flaring, obesity drug hits goal in liver disease study

State Dept. review finds Biden bears some blame for Afghanistan failures

Health AI adoption puts security, privacy startups on investors' radar

Psychedelics group wrestles with new pharma identity

The Harvard botanist who searched for psychedelics in the Amazon

Medicare details structure of new drug price negotiation program

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

focus

5 to watch: Tech startups trying to solve health care's staffing crisis

The Harvard botanist who searched for psychedelics in the Amazon

Medicare inequities exacerbate Puerto Rico’s health disparities

Alabama frozen embryo ruling has major implications for IVF clinics

Physicians and social media: If you see something, say something?

Obesity drugs seen as possible treatment for liver disease MASH

focus

knowledge

hotspot

Wikipedia